1Akarca US, Greene S and Log ASF. Detection of precore hepatitis B virus mutants in asympotomatic HBsAg-positive family members. Hepatology, 1994,19(6): 1366-1340.
2Chen H S,Kew MC,Hornbuckkle WE,et al. The precore gene of the woodchuck hepatitis virus genome is not essential for viral replication in the nature host. J Virol, 1992,66(9):5682-5684.
3Carman WF and Thomas HC. Genetic variation in hepatitis B virus. Gastroenterology, 1992,102(2) :711-719.
5Baumert TF,Rogers SA,Hasegawa K,et al. Two core promoter mutations identified in a hepatitis B virus strain associated with fulminant hepatits result in enhanced viral replication,J Clin Invest, 1996,98(10) :2268-2276.
6Brunetto MRF, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatits B accompanied by antibody to hepatitis B e antigen. Hepatology, 1989,10( 2 ): 198 ～ 202.
7Fattovich G,Farci P,Rugge M,et al.A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatits B lacking HBeAg. Hepatology, 1 992,15: (4)584-589.
8Berg T and Hopf U. Therapie der chronischen Virushepatitis. Deutsche med.Wochenschrift, 1997,122:1593-1598.
9Doong SL,Tsai CH,Schinazi RF,et al. Inhibition of the replication of hepatitis B virus in vitro by 2' 3'-dideoxy-3′-thaicytidine and related analogues. Proc Natl Acad Sci USA, 1991,88(19) :8495-8499.
10Tyrrell DLJ,Fischer K,Sayani K, et al. Treatment of chimpanzees and ducks with lamivudine 2'-3'-dideoxy-3 '-thiacytine results in a rapid suppression of hepadnaviral DNA in sera. Clin Invest Med,1993,15(Supp)487:B77.
3Gish RG, Locarnini SA. Chronic hepatitis B : current testing strategies [ J ]. Clin Gastroenterol Hepatol. , 2006 , 4 (6) :666
4Keeffe EB, Zeuzem S, Koff RS et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B [ J ]. Clin Gastroenterol Hepatol,2007,5 (8) : 890
5Husa P, Plisek S, Sperl J et al. Diagnosis and treatment of chronic hepatitis B [ J ]. Vnitr Lek,2007, 53 ( 11 ) : 1 221
6Fung SK, Lok AS. Update on viral hepatitis in 2004 [ J ]. Curr Opin Gastroenterol,2005,21 (3) :300
7Marcellin P, Chang TT, Lira SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis HBeAg antigenpositive chronic hepatitis B. Hepatology, 2008, 48(3): 750.
8Suh HJ, Park MK, Lee Hie, et al. Antiviral efficacy of lamivudine/ adefovir combination therapy in chronic hepatitis B patients with resistance to lamivudine and adefovir consecutively. Korean J Gastroenterol, 2009, 53(5) : 305.
9Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadrnap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol, 2007, 5(8): 890.
10Macellin P, Chang TT, Lira S, et al. Long term efficacy and safety of adefovir dipivoxil 10mg in HBeAg^1 chronic hepatitis B patients: increasing serologic, virologic and biochemical response over time Hepatology, 2004, 40(4 suppl): 655A.
